• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法布里病心肌病:心内膜糖鞘脂分隔的超声心动图检测

Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization.

作者信息

Pieroni Maurizio, Chimenti Cristina, De Cobelli Francesco, Morgante Emanuela, Del Maschio Alessandro, Gaudio Carlo, Russo Matteo Antonio, Frustaci Andrea

机构信息

Ospedale Multimedica, Milan, Italy.

出版信息

J Am Coll Cardiol. 2006 Apr 18;47(8):1663-71. doi: 10.1016/j.jacc.2005.11.070. Epub 2006 Mar 29.

DOI:10.1016/j.jacc.2005.11.070
PMID:16631007
Abstract

OBJECTIVES

We sought to identify echocardiographic hallmarks of Fabry's disease cardiomyopathy (FC).

BACKGROUND

The recognition of FC from other forms of left ventricular hypertrophy (LVH) by noninvasive imaging techniques is not yet available, and diagnosis, mostly in the absence of systemic manifestations, still relies on genetic and invasive studies.

METHODS

Forty consecutive patients (mean age 39 +/- 15 years, 22 men and 18 women) with an established diagnosis of Fabry's disease were submitted to echocardiographic evaluation. Control population consisted of 40 consecutive patients with hypertrophic cardiomyopathy (HCM), 40 hypertensive patients with echocardiographic evidence of LVH, and 40 age- and gender-matched healthy subjects with no LVH. All HCM patients and FC with LVH and/or cardiac symptoms underwent cardiac catheterization with left ventricular endomyocardial biopsy.

RESULTS

Echocardiography showed in 83% of FC patients (95% of FC patients with LVH) a binary appearance of endocardial border absent in all HCM, hypertensive, and healthy subjects. The sensitivity and specificity of this echocardiographic feature in detecting Fabry patients in study population were 94% and 100%, respectively. Comparison of echocardiographic with histologic and ultrastructural findings showed the binary appearance to reflect an endomyocardial glycosphingolipids compartmentalization, consisting of thickened glycolipid-rich endocardium, free glycosphingolipid subendocardial storage, and an inner severely affected myocardial layer with a clear subendocardial-midwall layer gradient of disease severity.

CONCLUSIONS

Echocardiographic binary appearance of left ventricular endocardial border, reflecting endomyocardial glycosphingolipids compartmentalization, represents a sensitive and specific diagnostic hallmark of Fabry's disease cardiomyopathy.

摘要

目的

我们试图确定法布里病心肌病(FC)的超声心动图特征。

背景

通过无创成像技术将FC与其他形式的左心室肥厚(LVH)区分开来的方法尚不可用,并且在大多数没有全身表现的情况下,诊断仍依赖于基因和侵入性研究。

方法

40例确诊为法布里病的连续患者(平均年龄39±15岁,男性22例,女性18例)接受了超声心动图评估。对照组包括40例连续的肥厚型心肌病(HCM)患者、40例有超声心动图证据显示LVH的高血压患者以及40例年龄和性别匹配且无LVH的健康受试者。所有HCM患者以及有LVH和/或心脏症状的FC患者均接受了左心室心内膜心肌活检的心脏导管检查。

结果

超声心动图显示,83%的FC患者(95%有LVH的FC患者)的心内膜边界呈现出一种二元形态,这在所有HCM、高血压和健康受试者中均未出现。在研究人群中,这种超声心动图特征检测法布里病患者的敏感性和特异性分别为94%和100%。超声心动图结果与组织学和超微结构结果的比较显示,这种二元形态反映了心内膜糖鞘脂的分隔,包括增厚的富含糖脂的心内膜、游离糖鞘脂的心内膜下储存以及内层严重受累的心肌层,且疾病严重程度在心内膜下-中壁层有明显梯度。

结论

左心室心内膜边界的超声心动图二元形态,反映了心内膜糖鞘脂的分隔,是法布里病心肌病敏感且特异的诊断特征。

相似文献

1
Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization.法布里病心肌病:心内膜糖鞘脂分隔的超声心动图检测
J Am Coll Cardiol. 2006 Apr 18;47(8):1663-71. doi: 10.1016/j.jacc.2005.11.070. Epub 2006 Mar 29.
2
Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance.法布里病的超声心动图检查:心内膜边界二元外观的诊断价值
Clin Physiol Funct Imaging. 2009 May;29(3):177-80. doi: 10.1111/j.1475-097X.2008.00851.x.
3
Early segmental relaxation abnormalities in hypertrophic cardiomyopathy for differential diagnostic of patients with left ventricular hypertrophy.肥厚型心肌病早期节段性舒张异常对左心室肥厚患者的鉴别诊断价值
Clin Cardiol. 2017 Nov;40(11):1026-1032. doi: 10.1002/clc.22761. Epub 2017 Jul 24.
4
[Four cases of Fabry's disease mimicking hypertrophic cardiomyopathy].[四例酷似肥厚型心肌病的法布里病病例]
J Cardiol. 1988 Sep;18(3):705-18.
5
New insights in cardiac structural changes in patients with Fabry's disease.法布里病患者心脏结构变化的新见解。
Am Heart J. 2000 Jun;139(6):1101-8. doi: 10.1067/mhj.2000.105105.
6
Is left ventricular hypertrabeculation/ noncompaction a cardiac manifestation of Fabry's disease?左心室肌小梁增多/心肌致密化不全是法布里病的心脏表现吗?
Z Kardiol. 2003 Nov;92(11):966-9. doi: 10.1007/s00392-003-1018-0.
7
Echocardiographic strain in hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy.肥厚型心肌病和高血压性左心室肥厚中的超声心动图应变
Echocardiography. 2019 Feb;36(2):257-265. doi: 10.1111/echo.14222. Epub 2018 Dec 18.
8
Early detection of Fabry cardiomyopathy by tissue Doppler imaging.通过组织多普勒成像早期检测法布里心肌病。
Circulation. 2003 Apr 22;107(15):1978-84. doi: 10.1161/01.CIR.0000061952.27445.A0. Epub 2003 Mar 31.
9
Biopsy-proven cardiomyopathy in heterozygous Fabry's disease.经活检证实的杂合子型法布里病心肌病。
Jpn Circ J. 1999 Jul;63(7):572-5. doi: 10.1253/jcj.63.572.
10
Cardiopulmonary involvement in Fabry's disease.法布里病的心肺受累情况。
Acta Cardiol. 2010 Apr;65(2):185-92. doi: 10.2143/AC.65.2.2047052.

引用本文的文献

1
Current status of the immunogenicity of enzyme replacement therapy in fabry disease.法布里病酶替代疗法的免疫原性现状
Orphanet J Rare Dis. 2025 May 26;20(1):253. doi: 10.1186/s13023-025-03705-4.
2
The role of sphingolipids in heart failure.鞘脂类在心力衰竭中的作用。
Eur Heart J Open. 2025 May 2;5(3):oeaf035. doi: 10.1093/ehjopen/oeaf035. eCollection 2025 May.
3
Fabry Cardiomyopathy: Myocardial Fibrosis, Inflammation, and Down-Regulation of Mannose-6-Phosphate Receptors Cause Low Accessibility to Enzyme Replacement Therapy.
法布里心肌病:心肌纤维化、炎症以及甘露糖-6-磷酸受体的下调导致酶替代疗法的可及性降低。
J Am Heart Assoc. 2025 Feb 18;14(4):e036815. doi: 10.1161/JAHA.124.036815. Epub 2025 Feb 8.
4
Case Report: Diagnostic challenges in Fabry disease: misinterpreted obstructive hypertrophic cardiomyopathy and the role of enzyme replacement therapy.病例报告:法布里病的诊断挑战:误诊为梗阻性肥厚型心肌病及酶替代疗法的作用
Front Cardiovasc Med. 2024 Nov 22;11:1479374. doi: 10.3389/fcvm.2024.1479374. eCollection 2024.
5
Role of standard echocardiography in Anderson-Fabry disease.标准超声心动图在安德森-法布里病中的作用。
Front Cardiovasc Med. 2024 Oct 24;11:1467815. doi: 10.3389/fcvm.2024.1467815. eCollection 2024.
6
The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies.法布里病中的心脏:储存之外的机制及未来疗法
Rev Cardiovasc Med. 2022 May 27;23(6):196. doi: 10.31083/j.rcm2306196. eCollection 2022 Jun.
7
Fabry Disease Cardiomyopathy: A Review of the Role of Cardiac Imaging from Diagnosis to Treatment.法布里病心肌病:从诊断到治疗的心脏成像作用综述
Rev Cardiovasc Med. 2022 May 27;23(6):192. doi: 10.31083/j.rcm2306192. eCollection 2022 Jun.
8
Echocardiography in Anderson-Fabry Disease.安德森-法布里病的超声心动图检查
Rev Cardiovasc Med. 2022 May 31;23(6):201. doi: 10.31083/j.rcm2306201. eCollection 2022 Jun.
9
Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy.肥厚型 Fabry 病心肌病酶替代治疗的长期临床病理结果。
J Am Heart Assoc. 2024 Apr 16;13(8):e032734. doi: 10.1161/JAHA.123.032734. Epub 2024 Apr 2.
10
Position Statement on the Use of Myocardial Strain in Cardiology Routines by the Brazilian Society of Cardiology's Department Of Cardiovascular Imaging - 2023.《关于心肌应变在心血管影像学分会常规心脏病学中的应用的立场声明——2023》。
Arq Bras Cardiol. 2023 Dec;120(12):e20230646. doi: 10.36660/abc.20230646.